ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
41 announcements
Granules India reported Q4FY26 revenue of ₹1470.6 Crore, up 23% YoY, with PAT rising 33% to ₹201.6 Crore. Annual FY26 revenue reached ₹5,365.6 Crore, a 20% growth. Performance was driven by portfolio expansion and the Peptides CDMO platform, alongside significant debt reduction and improved ROCE of 17.6%.
Granules India achieved a landmark FY26 with revenue surpassing ₹50,000 Mn, driven by a structural shift towards high-margin Complex Gx and Peptide CDMO segments.
Granules India achieved a landmark FY26 with revenue surpassing ₹50,000 Mn, driven by a structural shift toward high-margin Complex Gx and Peptide CDMO.
Granules India Limited has designated Executive Director Mr. Harsha Chigurupati as Senior Management Personnel (SMP) effective April 30, 2026. He will lead Transformation, Information Technology, Project Management, and Leadership Hiring. The appointment aims to strengthen the company's senior leadership and strategic oversight.
Granules India Limited reported consolidated total income of ₹5,385.97 Crore for FY 2025-26. The Board recommended a final dividend of ₹1.75 per share. Key developments include the acquisition of Senn Chemicals AG and a USFDA warning letter for the Gagillapur facility, which impacted production and revenue.
Granules India Ltd reported revenue from operations of ₹1,471 Cr (+22.8% YoY) and net profit of ₹201.6 Cr (+32.6% YoY) for Q4 FY26.
Granules India approved audited financial results for FY 2025-26 and recommended a final dividend of Rs. 1.75 per share (175%). Standalone annual net profit reached ₹400.67 Crore. The company also fixed its 35th AGM for August 06, 2026, and a dividend record date of July 30, 2026.
Granules India Limited has scheduled a Board Meeting on April 29, 2026. The board will consider audited financial results for Q4 and FY2025-26 and recommend a final dividend. The insider trading window remains closed until May 1, 2026.
Granules India Ltd reported net profit of ₹150 Cr (+27.1% YoY) for Q3 FY26.
Granules India Ltd has submitted its initial disclosure confirming it does not fall under the Large Corporate category as per SEBI criteria. The company reported zero outstanding borrowings as of the relevant financial period and committed to informing the exchange if its status changes in the future.
Granules India's US subsidiary, GPI, completed a routine US FDA cGMP audit at its Chantilly, Virginia site with four procedural observations. The inspection, conducted from March 30 to April 3, 2026, reported no data integrity issues. The company committed to addressing the observations within stipulated timelines to maintain regulatory compliance.